Modi S - Search Results

1

Paradigms for Precision Medicine in Epichaperome Cancer Therapy.

Pillarsetty N, Jhaveri K, Taldone T, Caldas-Lopes E, Punzalan B, Joshi S, Bolaender A, Uddin MM, Rodina A, Yan P, Ku A, Ku T, Shah SK, Lyashchenko S, Burnazi E, Wang T, Lecomte N, Janjigian Y, Younes A, Batlevi CW, Guzman ML, Roboz GJ, Koziorowski J, Zanzonico P, Alpaugh ML, Corben A, Modi S, Norton L, Larson SM, Lewis JS, Chiosis G, Gerecitano JF, Dunphy MPS. Pillarsetty N, et al. Among authors: modi s. Cancer Cell. 2019 Nov 11;36(5):559-573.e7. doi: 10.1016/j.ccell.2019.09.007. Epub 2019 Oct 24. Cancer Cell. 2019. PMID: 31668946 Free PMC article.

2

Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer.

Modi S, Panageas KS, Duck ET, Bach A, Weinstock N, Dougherty J, Cramer L, Hudis C, Norton L, Seidman A. Modi S, et al. J Clin Oncol. 2002 Sep 1;20(17):3665-73. doi: 10.1200/JCO.2002.08.057. J Clin Oncol. 2002. PMID: 12202668 Clinical Trial.

3

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.

Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan LK, Norton L, Hudis CA. Modi S, et al. Breast Cancer Res Treat. 2005 Mar;90(2):157-63. doi: 10.1007/s10549-004-3974-0. Breast Cancer Res Treat. 2005. PMID: 15803362 Clinical Trial.

4

A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.

Modi S, Currie VE, Seidman AD, Bach AM, Panageas KS, Theodoulou M, Moasser MM, D'Andrea GM, Lake DE, Choi J, Norton L, Hudis CA. Modi S, et al. Clin Breast Cancer. 2005 Apr;6(1):55-60. doi: 10.3816/CBC.2005.n.009. Clin Breast Cancer. 2005. PMID: 15899073 Clinical Trial.

5

Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.

Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Fornier MN, et al. Among authors: modi s. Cancer. 2005 Oct 15;104(8):1575-9. doi: 10.1002/cncr.21385. Cancer. 2005. PMID: 16134178 Free article.

6

Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.

Modi S, DiGiovanna MP, Lu Z, Moskowitz C, Panageas KS, Van Poznak C, Hudis CA, Norton L, Tan L, Stern DF, Carter D, Seidman AD. Modi S, et al. Cancer Invest. 2005;23(6):483-7. doi: 10.1080/07357900500201301. Cancer Invest. 2005. PMID: 16203655

7

A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer.

Modi S, D'Andrea G, Norton L, Yao TJ, Caravelli J, Rosen PP, Hudis C, Seidman AD. Modi S, et al. Clin Breast Cancer. 2006 Aug;7(3):270-7. doi: 10.3816/CBC.2006.n.040. Clin Breast Cancer. 2006. PMID: 16942645 Clinical Trial.

8

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, Johnson RG, Hannah AL, Hudis CA. Modi S, et al. J Clin Oncol. 2007 Dec 1;25(34):5410-7. doi: 10.1200/JCO.2007.11.7960. J Clin Oncol. 2007. PMID: 18048823 Clinical Trial.

9

Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results.

Morris PG, Poznak CV, Modi S, Mak AF, Patil S, Larson S, Hudis CA, Divgi C, Grewal RK. Morris PG, et al. Among authors: modi s. Clin Breast Cancer. 2010 Feb;10(1):33-9. doi: 10.3816/CBC.2010.n.004. Clin Breast Cancer. 2010. PMID: 20133256 Clinical Trial.

10

HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, D'Andrea G, Dickler M, Moynahan ME, Sugarman S, Ma W, Patil S, Norton L, Hannah AL, Hudis C. Modi S, et al. Clin Cancer Res. 2011 Aug 1;17(15):5132-9. doi: 10.1158/1078-0432.CCR-11-0072. Epub 2011 May 10. Clin Cancer Res. 2011. PMID: 21558407 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

676 results

Search Page